421 related articles for article (PubMed ID: 32653774)
1. Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective study.
de Vries-Brilland M; Gross-Goupil M; Seegers V; Boughalem E; Beuselinck B; Thibault C; Chevreau C; Ladoire S; Barthélémy P; Negrier S; Borchiellini D; Huillard O; Geoffrois L; Gravis G; Saldana C; Thiery-Vuillemin A; Escudier B; Ravaud A; Albiges L
Eur J Cancer; 2020 Sep; 136():76-83. PubMed ID: 32653774
[TBL] [Abstract][Full Text] [Related]
2. The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma.
McKay RR; Bossé D; Xie W; Wankowicz SAM; Flaifel A; Brandao R; Lalani AA; Martini DJ; Wei XX; Braun DA; Van Allen E; Castellano D; De Velasco G; Wells JC; Heng DY; Fay AP; Schutz FA; Hsu J; Pal SK; Lee JL; Hsieh JJ; Harshman LC; Signoretti S; Motzer RJ; Feldman D; Choueiri TK
Cancer Immunol Res; 2018 Jul; 6(7):758-765. PubMed ID: 29748390
[TBL] [Abstract][Full Text] [Related]
3. Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma.
McGregor BA; Lalani AA; Xie W; Steinharter JA; E Bakouny Z; Martini DJ; Fleischer JH; Abou-Alaiwi S; Nassar A; Nuzzo PV; Kaymakcalan MD; Braun DA; Wei XX; Harshman LC; Bilen MA; Choueiri TK
Eur J Cancer; 2020 Aug; 135():203-210. PubMed ID: 32599410
[TBL] [Abstract][Full Text] [Related]
4. Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Yip SM; Wells C; Moreira R; Wong A; Srinivas S; Beuselinck B; Porta C; Sim HW; Ernst DS; Rini BI; Yuasa T; Basappa NS; Kanesvaran R; Wood LA; Canil C; Kapoor A; Fu SYF; Choueiri TK; Heng DYC
Cancer; 2018 Sep; 124(18):3677-3683. PubMed ID: 30307610
[TBL] [Abstract][Full Text] [Related]
5. Checkpoint inhibitors in metastatic papillary renal cell carcinoma.
de Vries-Brilland M; McDermott DF; Suárez C; Powles T; Gross-Goupil M; Ravaud A; Flippot R; Escudier B; Albigès L
Cancer Treat Rev; 2021 Sep; 99():102228. PubMed ID: 34111642
[TBL] [Abstract][Full Text] [Related]
6. Co-Regulation of Immune Checkpoint PD-L1 with Interferon-Gamma Signaling is Associated with a Survival Benefit in Renal Cell Cancer.
Hänze J; Wegner M; Noessner E; Hofmann R; Hegele A
Target Oncol; 2020 Jun; 15(3):377-390. PubMed ID: 32495158
[TBL] [Abstract][Full Text] [Related]
7. Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial.
Vaishampayan U; Schöffski P; Ravaud A; Borel C; Peguero J; Chaves J; Morris JC; Kotecki N; Smakal M; Zhou D; Guenther S; Bajars M; Gulley JL
J Immunother Cancer; 2019 Oct; 7(1):275. PubMed ID: 31651359
[TBL] [Abstract][Full Text] [Related]
8. Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma.
McDermott DF; Lee JL; Ziobro M; Suarez C; Langiewicz P; Matveev VB; Wiechno P; Gafanov RA; Tomczak P; Pouliot F; Donskov F; Alekseev BY; Shin SJ; Bjarnason GA; Castellano D; Silverman RK; Perini RF; Schloss C; Atkins MB
J Clin Oncol; 2021 Mar; 39(9):1029-1039. PubMed ID: 33529058
[TBL] [Abstract][Full Text] [Related]
9. Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial.
Feldman DR; Ged Y; Lee CH; Knezevic A; Molina AM; Chen YB; Chaim J; Coskey DT; Murray S; Tickoo SK; Reuter VE; Patil S; Xiao H; Aghalar J; Apollo AJ; Carlo MI; Motzer RJ; Voss MH
Cancer; 2020 Dec; 126(24):5247-5255. PubMed ID: 32975815
[TBL] [Abstract][Full Text] [Related]
10. Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial.
Negrier S; Rioux-Leclercq N; Ferlay C; Gross-Goupil M; Gravis G; Geoffrois L; Chevreau C; Boyle H; Rolland F; Blanc E; Ravaud A; Dermeche S; Flechon A; Albiges L; Pérol D; Escudier B;
Eur J Cancer; 2020 Apr; 129():107-116. PubMed ID: 32146304
[TBL] [Abstract][Full Text] [Related]
11. Patients with sarcomatoid renal cell carcinoma - re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors.
Iacovelli R; Ciccarese C; Bria E; Bracarda S; Porta C; Procopio G; Tortora G
Eur J Cancer; 2020 Sep; 136():195-203. PubMed ID: 32712550
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab for the Treatment of Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC): A Single-Institutional Experience and Literature Meta-Analysis.
Chahoud J; Msaouel P; Campbell MT; Bathala T; Xiao L; Gao J; Zurita AJ; Shah AY; Jonasch E; Sharma P; Tannir NM
Oncologist; 2020 Mar; 25(3):252-258. PubMed ID: 32162795
[TBL] [Abstract][Full Text] [Related]
13. Clinical Outcomes of Metastatic Renal Carcinoma Following Disease Progression to Programmed Death (PD)-1 or PD-L1 Inhibitors (IO): A Meet-URO Group Real World Study (Meet-Uro 7).
Santini D; Stellato M; De Giorgi U; Pantano F; De Lisi D; Casadei C; Maruzzo M; Bimbatti D; Naglieri E; Buti S; Bersanelli M; De Vivo R; Di Lorenzo G; Sbrana A; Verzoni E; Soraru' M; Fornarini G; Mucciarini C; Grillone F; Mini E; Vignani F; Attademo L; Pignata S; Procopio G
Am J Clin Oncol; 2021 Mar; 44(3):121-125. PubMed ID: 33617179
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy.
Graham J; Wells JC; Dudani S; Gan CL; Donskov F; Lee JL; Kollmannsberger CK; Meza L; Beuselinck B; Hansen A; North SA; Bjarnason GA; Sayegh N; Kanesvaran R; Wood LA; Hotte SJ; McKay RR; Choueiri TK; Heng DYC
Eur J Cancer; 2022 Aug; 171():124-132. PubMed ID: 35717820
[TBL] [Abstract][Full Text] [Related]
15. Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma.
Koshkin VS; Barata PC; Zhang T; George DJ; Atkins MB; Kelly WJ; Vogelzang NJ; Pal SK; Hsu J; Appleman LJ; Ornstein MC; Gilligan T; Grivas P; Garcia JA; Rini BI
J Immunother Cancer; 2018 Jan; 6(1):9. PubMed ID: 29378660
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors.
Chahoud J; Msaouel P; Ross JA; McCormick BZ; Bathala TK; Gao J; Horn R; Xiao L; Sircar K; Campbell MT; Shah AY; Goswami S; Zurita AJ; Jonasch E; Matin SF; Wood CG; Karam JA; Sharma P; Tannir NM
Urol Oncol; 2021 Feb; 39(2):134.e9-134.e16. PubMed ID: 33187886
[TBL] [Abstract][Full Text] [Related]
17. Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events.
Martini DJ; Hamieh L; McKay RR; Harshman LC; Brandao R; Norton CK; Steinharter JA; Krajewski KM; Gao X; Schutz FA; McGregor B; Bossé D; Lalani AA; De Velasco G; Michaelson MD; McDermott DF; Choueiri TK
Cancer Immunol Res; 2018 Apr; 6(4):402-408. PubMed ID: 29437040
[TBL] [Abstract][Full Text] [Related]
18. Increased expression of adenosine 2A receptors in metastatic renal cell carcinoma is associated with poorer response to anti-vascular endothelial growth factor agents and anti-PD-1/Anti-CTLA4 antibodies and shorter survival.
Kamai T; Kijima T; Tsuzuki T; Nukui A; Abe H; Arai K; Yoshida KI
Cancer Immunol Immunother; 2021 Jul; 70(7):2009-2021. PubMed ID: 33416945
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma.
Abou Alaiwi S; Xie W; Nassar AH; Dudani S; Martini D; Bakouny Z; Steinharter JA; Nuzzo PV; Flippot R; Martinez-Chanza N; Wei X; McGregor BA; Kaymakcalan MD; Heng DYC; Bilen MA; Choueiri TK; Harshman LC
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32066646
[TBL] [Abstract][Full Text] [Related]
20. Hyperprogressive Disease in Patients With Urothelial Carcinoma or Renal Cell Carcinoma Treated With PD-1/PD-L1 Inhibitors.
Hwang I; Park I; Yoon SK; Lee JL
Clin Genitourin Cancer; 2020 Apr; 18(2):e122-e133. PubMed ID: 31837940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]